Table 1 Clinical characteristics of patients in the MIRI and non-MIRI groups
From: Prediction of myocardial ischemia–reperfusion injury post-PCI: role of sST2 levels in STEMI patients
Variable | non-MIRI group (n=137) | MIRI group (n=86) | P |
|---|---|---|---|
Baseline characteristics | |||
Male sex,n (%) | 112 (81.8) | 63 (73.3) | 0.133 |
Age,y | 60.28±12.28 | 61.56±13.15 | 0.461 |
Body mass index,( kg/m2) | 24.69±3.34 | 25.35±3.84 | 0.178 |
Hypertension ,n (%) | 65 (47.40) | 39 (45.43) | 0.760 |
Diabetes mellitusn,n (%) | 34 (24.8) | 27 (31.4) | 0.283 |
Smoking,n (%) | 84 (61.3) | 50 (58.1) | 0.638 |
sST2 (ng/mL) | 41.08 (29.30, 53.72) | 73.17 (51.56, 86.27) | <0.001 |
Blood uric acid (μmol/L) | 327 (268.5, 396.5) | 326 (276.5, 417.5) | 0.356 |
Fasting blood glucose (mmol/L) | 6.10 (5.18, 8.36) | 6.55 (5.64, 8.35) | 0.230 |
Hemoglobin (g/L) | 146 (138, 155) | 144 (133, 154) | 0.262 |
Platelet count (109 /L) | 228 (191, 280) | 233 (195, 273) | 0.928 |
NLR | 3.77 (2.39, 6.34) | 5.05 (2.50, 9.09) | 0.060 |
Total cholesterol (`x ±s, mmol/L) | 4.93±1.25 | 4.75±1.08 | 0.293 |
LDL-c (`x ±s, mmol/L) | 3.08 (2.59, 3.70) | 2.99 (2.52, 3.44) | 0.298 |
Lp(a) (g/L) | 108.1 (63.5, 233.9) | 157.9 (88.2, 260.9) | 0.042 |
HDL-c (mmol/L) | 1.02 (0.87, 1.20) | 0.97 (0.85, 1.17) | 0.290 |
Peak NT-proBNP (pg/mL) | 977 (426, 2035) | 1515 (728, 2972) | 0.003 |
Peak CK-MB (U/L) | 73.4 (35.75, 148.5) | 122 (65.4, 201.7) | 0.007 |
Peak cTnI (μg/L) | 34.7 (14.1, 80.0) | 59.5 (35.4, 80.0) | 0.001 |
LEDV (mL) | 97 (89, 110) | 100 (89, 115) | 0.362 |
LESV (mL) | 55 (49, 62) | 56 (52, 67) | 0.196 |
LVEF | 0.42 (0.40, 0.46) | 0.41 (0.38, 0.45) | 0.117 |
Symptom-to-balloon time (h) | 5.42 (3.33, 9.09) | 7.51 (3.00, 8.55) | 0.426 |
Killip classification ≥ II,n (%) | 16 (11.7%) | 14 (16.3%) | 0.327 |
Angiographic and procedural characteristics | |||
High thrombotic load ,n (%) | 29 (21.2) | 41 (47.7) | <0.001 |
Number of blood vessels ,n (%) | |||
Single vessel disease | 35 (25.5) | 24 (27.9) | 0.697 |
Multivessel disease | 41 (74.5) | 60 (69.8) | |
IRA,n (%) | |||
LM | 11 (8.0) | 6 (7.0) | 0.009 |
LAD | 68 (49.6) | 30 (34.9) | |
LCX | 21 (15.3) | 8 (9.3) | |
RCA | 48 (55.8) | 49 (35.8) | |
Site of lesion,n (%) | |||
Proximal | 47 (34.3) | 44 (51.2) | 0.030 |
Middle | 61 (44.5) | 23 (26.7) | |
Distal | 36 (26.3) | 19 (22.1) | |
Immediate postoperative blood pressure (beats/min) | |||
Systolic blood pressure | 130 (118, 151) | 128 (116, 142) | 0.165 |
Diastolic blood pressure | 83 (75, 90) | 78 (70, 87) | 0.024 |
Total stent length (mm) | 34 (24, 54) | 36 (25, 58) | 0.292 |
Lateral branch formation | 13 (9.5) | 12 (14.0) | 0.304 |
Gensini | 54 (39.5, 84.0) | 57.5 (41.8, 84.0) | 0.578 |
SYNTAX | 17.6(12.2, 26.4) | 20.05(14.1, 25.9) | 0.295 |
TIMI pre-PCI≤1,n (%) | 73 (53.3%) | 61 (70.9%) | 0.009 |
TIMI post-PCI≤2,n (%) | 0 (0.00%) | 16 (18.6%) | <0.001 |
Manual thrombus aspiration,n (%) | 24 (17.5%) | 29 (33.7%) | 0.006 |
Medication | |||
Aspirin,n (%) | 137 (100.0%) | 83 (96.5%) | 0.056 |
P2Y12 inhibitorn,n (%) | 136 (99.3%) | 85 (98.8%) | 1.000 |
Clopidogre,n (%) | 119 (86.9%) | 76 (86.4%) | 0.740 |
Ticagrelor,n (%) | 17 (12.4%) | 9 (10.5%) | 0.660 |
Glycoprotein IIb/IIIa antagonists,n (%) | 58 (42.3%) | 35 (40.7%) | 0.809 |
β-blockers,n (%) | 86 (62.8%) | 44 (51.2%) | 0.087 |
RAAS blockers,n (%) | 68 (49.6%) | 33 (38.4%) | 0.100 |
Adenosine,n (%) | 1 (0.70%) | 36 (41.9%) | <0.001 |